Literature DB >> 3029234

The H-2 complex regulates both the susceptibility to mouse viral lymphomagenesis and the phenotype of the virus-induced lymphomas.

M Zijlstra, W L Vasmel, T Radaskiewicz, E Matthews, C J Melief.   

Abstract

Neonatal infection of C57BL/10 mice with cloned ecotropic and/or dualtropic mink cell focus-inducing (MCF) mouse leukaemia viruses (MuLV), induces a wide spectrum of different lymphomas of T, B, and non-T/non-B cell types. The H-2 complex has a marked influence on both the development of lymphoma incidence and lymphoma type. A study using the oncogenic MCF 1233 virus and a series of B10 congenic mice enabled the mapping of the following: Resistance to the early development of T cell lymphoma is controlled by the H-2I-A locus. Susceptibility to early T cell lymphomagenesis is associated with an I-A-regulated low anti-MCF 1233 envelope antibody response and persistent infection of the thymus. B10 (H-2b) mice, which are resistant to early T cell lymphomagenesis induced by MCF 1233 or other MuLV isolates, have high anti-MuLV envelope antibody responses which are I-A-regulated. These mice develop more B cell lymphomas late in life in contrast to the early development of T cell lymphoma in B10.A (H-2a) mice. The possible response mechanisms which underlie these observations, including: I-A-regulated immunoselection against MuLV antigens expressed by (pre) leukaemic T cells, aberrant expression of class II MHC antigens on some B cell lymphomas and I-A-regulated chronic immunostimulation of MuLV-expressing (pre) leukaemic B cells, are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3029234     DOI: 10.1111/j.1744-313x.1986.tb01086.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  1 in total

1.  A quantitative trait locus in major histocompatibility complex determining latent period of mouse lymphomas.

Authors:  T Kamoto; H Shisa; A Pataer; L Lu; O Yoshida; Y Yamada; H Hiai
Journal:  Jpn J Cancer Res       Date:  1996-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.